What was the financial performance of Boston Scientific in 2006?

In 2006, Boston Scientific's net sales increased to $7.821 billion, largely due to the acquisition of Guidant Corporation. However, the company reported a net loss of $3.577 billion ($2.81 per diluted share) compared to a net income of $628 million ($0.75 per diluted share) in 2005. This loss was primarily driven by significant one-time charges related to the Guidant acquisition, including purchase accounting adjustments and integration costs.

What were the key strategic moves made by Boston Scientific in 2006?

The most significant strategic move was the acquisition of Guidant Corporation for $28.4 billion, which substantially expanded Boston Scientific's presence in the cardiac rhythm management and cardiac surgery markets. The company also continued to invest in its product portfolio, particularly in drug-eluting stents and CRM technologies, while managing integration and regulatory challenges.

What challenges did Boston Scientific face in 2006, particularly regarding its products?

The company faced challenges in its coronary stent business, with sales declining due to market uncertainty surrounding the risk of late stent thrombosis associated with drug-eluting stents. This led to reduced market penetration and device utilization per procedure. Additionally, the Cardiac Rhythm Management (CRM) business experienced lower market growth rates and market share due to industry-wide field actions, although signs of stabilization were observed in the fourth quarter.

How did the Guidant acquisition impact the company's financial structure and outlook?

The Guidant acquisition significantly increased Boston Scientific's debt levels to $8.902 billion by the end of 2006, primarily financed through debt. This increased financial leverage requires a focus on debt repayment and cash flow management. The integration of Guidant presents opportunities for growth but also brings complex challenges, including restructuring costs and the need to re-establish market confidence in the CRM division.

What were the main regulatory issues faced by Boston Scientific in 2006?

Boston Scientific received a corporate warning letter from the FDA for quality system deficiencies at three facilities, indicating that a previously submitted corrective action plan was inadequate. This letter could impact future regulatory approvals. Additionally, Guidant received an FDA warning letter for its CRM facility, and Boston Scientific inherited these ongoing regulatory matters, actively working on remediation efforts.

BSX 10-K FY2006 Annual Report — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported its 2006 annual results, a year marked by the transformative acquisition of Guidant Corporation. This acquisition significantly expanded BSX's footprint, particularly in the Cardiac Rhythm Management (CRM) and Cardiac Surgery sectors, establishing it as a major player in cardiovascular devices. While the Guidant acquisition drove a substantial increase in net sales to $7.821 billion, the company reported a net loss of $3.577 billion for the year, primarily due to significant one-time acquisition-related charges, including purchase accounting adjustments and integration costs. The company faced challenges in its core coronary stent business, with sales declining due to market concerns over late stent thrombosis, although regulatory panels continued to affirm the safety and efficacy of drug-eluting stents. Despite the reported net loss, the company generated strong operating cash flow and maintained a focus on innovation and quality improvement. The integration of Guidant presented both opportunities and challenges, with ongoing restructuring efforts planned to optimize operations. BSX also addressed regulatory issues, including FDA warning letters at several facilities, and made progress on remediation efforts. Looking ahead, the company aimed to leverage its expanded product portfolio, particularly in the CRM and drug-eluting stent markets, while managing its debt obligations incurred from the Guidant acquisition.

Key Highlights

1Acquisition of Guidant Corporation for $28.4 billion, significantly expanding market presence in Cardiac Rhythm Management (CRM) and Cardiac Surgery.
2Net sales increased to $7.821 billion, driven by the Guidant acquisition, but the company reported a net loss of $3.577 billion due to acquisition-related charges.
3Coronary stent sales declined by 5% to $3.612 billion, impacted by market concerns regarding late stent thrombosis.
4CRM business revenue was $1.371 billion, with pro forma sales of $2.026 billion for the full year, showing a slight decline from 2005 but with signs of stabilization in Q4.
5Invested over $1 billion in Research and Development, representing approximately 13% of net sales, to drive future innovation.
6Addressed FDA warning letters at multiple facilities, implementing Project Horizon for quality process improvements and working towards remediation.
7Ended the year with $8.902 billion in outstanding debt, primarily related to the Guidant acquisition, and maintained investment-grade credit ratings.
8Securities litigation and shareholder derivative suits increased, partly due to the Guidant acquisition.

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2006

Summary

Key Highlights

Frequently Asked Questions